Diagnostic Access to Self-Care and Health Services in Low and Middle Income Countries (DASH) - Phase II

NCT06588790 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2250

Last updated 2024-09-19

No results posted yet for this study

Summary

Our primary goal is to determine if on-demand, home-based rapid testing, or rapid testing done by a community health worker (CHW) results in people testing for diseases more frequently and getting care more quickly. These two testing approaches will be compared to how individuals would normally test if they were concerned about certain diseases.

The main questions the study aims to answer are:

* Do either of the testing approaches result in more people testing themselves for certain diseases when needed?
* Does self-testing at home or testing done by a community health worker increase the number of individuals receiving test results and getting care/treatment more quickly?
* Does at-home screening for high blood pressure and diabetes result in lower blood pressure and hemoglobin A1c levels (an indicator for diabetes)?

Conditions

Interventions

OTHER

Home-based rapid testing

Participants will be provided with rapid diagnostic tests for HIV, pregnancy and malaria (in Kenya and Zambia only) for on-demand, at-home self testing if/when indicated.

OTHER

Community health worker rapid testing

Participants will have access to rapid testing through a community health worker who will conduct rapid testing in the home or at a community-based location when indicated.

Sponsors & Collaborators

  • Kenya Medical Research Institute

    collaborator OTHER
  • Centre for Infectious Disease Research in Zambia

    collaborator OTHER
  • Human Sciences Research Council

    collaborator OTHER_GOV
  • Bill and Melinda Gates Foundation

    collaborator OTHER
  • University of Washington

    lead OTHER

Principal Investigators

  • Paul Drain, MD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • Kenya
  • South Africa
  • Zambia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06588790 on ClinicalTrials.gov